CRESCENT-HEALTHCARE
The US Society of Robotic Surgery and Crescent Healthcare (a Division of the Crescent Group of Companies) host the first Global Robotic MedTech Forum in the Middle East on 16 March 2023 in Dubai. The event, the first dedicated global forum to gather world renowned experts in the region, will focus on the latest advancements in robotic surgery, a rapidly growing field that is revolutionizing healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005505/en/
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention (Photo: AETOSWire)
The Forum will host ministers, senior government officials, as well as healthcare, R&D and investment professionals to discuss the future of robotic assisted surgery, in addition to the UAE’s leading position at the cutting-edge of healthcare.
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention, commented: "As we navigate the challenges of modern healthcare, the UAE is proud to host the Global Robotic MedTech Forum. By embracing technology and innovation, we can further improve patient outcomes and provide more efficient and effective healthcare solutions for all."
Dr. Vipul Patel, President, Society of Robotic Surgery, and one of the world's most experienced robotic surgeons said: "The Forum will provide a unique platform for knowledge exchange and explore innovative solutions that can vastly help improve patient outcomes."
Mr. Hamid Jafar, Chairman of the Crescent Group of Companies, which is hosting the event, said: "The Global Robotic MedTech Forum is an important platform that brings together industry leaders to drive meaningful advancements in the healthcare sector. We are pleased to host this event and look forward to enabling the sharing of insights and knowledge in this exciting field."
Dr. Fred Moll, Founder of Intuitive Surgical and a pioneer of robotic surgery, said: "Honored to be part of the Forum and have the opportunity to share insights on the future of robotic surgery with fellow innovators and industry leaders."
Neeraj Agrawal, Board Member of EndoQuest, said: "This event brings together the best and brightest global minds in the field to the Gulf region, and we are honored to participate."
Kurt Azarbarzin, CEO of EndoQuest, added: "We are excited to present the latest innovations in scarless incisionless robotic surgery deploying flexible robots through natural human orifices."
Eduardo Fonseca, Board Member of XCath, commented: “From advanced imaging and sensors to cutting-edge robotics and AI, the possibilities for enhancing patient outcomes and improving the quality of care are endless. The Gulf region will be at the forefront of the development of groundbreaking technologies that have the potential to transform the healthcare industry."
The Global Robotic MedTech Forum will feature some of the most prominent global figures in the field of robotic surgery including Dr. Chris Thompson, Professor at Harvard University who has been at the forefront of developing and testing new robotic surgical techniques. Dr. Santiago Horgan, the Director of UC San Diego’s Center for the Future of Surgery will also share his insights. The participation of these distinguished experts underscores the importance of the Global Robotic MedTech Forum as a platform for sharing knowledge and advancing the field of robotic medicine.
The Forum will feature keynote speeches from leading experts in the field, interactive panel discussions, and hands-on demonstrations of the latest robotic surgical systems. Attendees will have the opportunity to learn about the latest advancements in the field, and to see first-hand how robotic surgery is rapidly changing the face of healthcare globally.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage20.10.2025 08:00:00 CEST | Press release
Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard’s Financial Sponsors Group, to further strengthen the firm’s presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/ Edouard Panié Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advising on more than 60 landmark M&A, debt, and equity transactions for leading alternative asset managers in private equity, growth equity, and infrastructure, as well as entrepreneurs, families, and corporates. “Private capital is playing an increasingly pivotal role in shaping industries and driving growth. Edouard’s extensive experience and relationships will strengthen Lazard’s ability to pro
Lone Star Announces Sale of Xella to Holcim20.10.2025 06:40:00 CEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 06:00:00 CEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom